Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H.
about
Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunityTherapeutic regulation of complement in patients with renal disease - where is the promise?Infections of People with Complement Deficiencies and Patients Who Have Undergone SplenectomyMutations in complement C3 predispose to development of atypical hemolytic uremic syndromeScreening for C3 deficiency in newborns using microarrays.New milestones ahead in complement-targeted therapy.Complement mediated signaling on pulmonary CD103(+) dendritic cells is critical for their migratory function in response to influenza infection.Meningococcal group W-135 and Y capsular polysaccharides paradoxically enhance activation of the alternative pathway of complement.Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity.Rare loss-of-function mutation in complement component C3 provides insight into molecular and pathophysiological determinants of complement activityCompstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape.Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathyGender-specific modulation of immune system complement gene expression in marine medaka Oryzias melastigma following dietary exposure of BDE-47.Therapeutic control of complement activation at the level of the central component C3.Autoantibody stabilization of the classical pathway C3 convertase leading to C3 deficiency and Neisserial sepsis: C4 nephritic factor revisited.Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention.Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.Progress and Trends in Complement TherapeuticsComplement in immune and inflammatory disorders: therapeutic interventions.Complement genetics, deficiencies, and disease associations.Rheumatoid arthritis and the complement system.CMAP: Complement Map Database.Low complement levels in paediatric systemic lupus erythematosus and the risk of bacteraemia.Complement inhibition in pre-clinical models of periodontitis and prospects for clinical applicationComplement activation: an emerging player in the pathogenesis of cardiovascular diseaseIntracellular complement activation sustains T cell homeostasis and mediates effector differentiation.Induction of complement C3a receptor responses by kallikrein-related peptidase 14.A novel immunodeficiency syndrome associated with partial trisomy 19p13.Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.A C3(H20) recycling pathway is a component of the intracellular complement system.Cutaneous manifestations of complement deficiencies.Disease-causing mutations in genes of the complement system.The immediate protective response to microbial challenge.Meningococcal polysaccharide vaccine failure in a patient with C7 deficiency and a decreased anti-capsular antibody response.Complement component C3 - The "Swiss Army Knife" of innate immunity and host defenseDifferential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus.From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.Complement factor H in host defense and immune evasion.Cardiovascular disease in haemodialysis: role of the intravascular innate immune system.
P2860
Q24672388-CF07CB27-452B-4809-A0FB-F79E3A664E42Q26851705-C4816831-DBC4-4272-BED7-A2474A21CED2Q28972389-9F96957A-A08C-4B67-8CF4-24CB26CB9DBBQ33381182-C09922F1-9D5A-4CF0-9733-AC0724C06080Q33434518-C4CADF37-D9AE-4592-AAA3-E860214DA3ADQ33602320-D56C31A9-4D18-44D1-B97D-AC8A277B24B1Q34550742-5A6DB586-75F0-4331-82EA-82E586615E3CQ34624357-DAC548E7-8A75-4945-9D61-C3A8003B5398Q34629133-688D82DC-9C0D-42BD-A9C4-5D941E2CC586Q35205450-DF9D00E3-049B-4930-B93D-93E3E2684663Q35236103-789D82C9-24ED-41C3-8611-932F1030C1AEQ35252156-8402C3DA-3CE9-4481-8205-5EBA567B9704Q35877192-FF148E46-7EC9-4750-AEB0-0DB512D63DC6Q36113743-20E35925-8CBB-429F-AAD1-AA07D1D84805Q36363005-AF7315B3-BCF6-4359-8915-3E67AA9A8D8AQ36409764-B41BA5A8-64A5-493E-90C5-56056AC485D6Q36460034-E2B054A9-A073-4349-9004-5A5259888CDDQ36463266-E62F2648-FAB2-483C-9206-57C248006C3CQ36479278-51C99266-98B6-40E8-9FE9-9654761FB20CQ36756854-F5B381EE-3F1A-4750-B5D1-1153F459611FQ36922946-9E903F99-28EE-4408-ADFD-B8AD6742CF71Q36939396-EC81F36A-997D-4F7C-A146-6BE606699110Q36984979-FA0294AF-B1B0-4B32-A959-9D1BD209F99BQ37145208-0961229B-F2E2-457D-A800-85A0E621B0BEQ37180462-1D30537A-4BE2-419E-A4B6-73CC0DFF1884Q37288362-2130DEB3-9BA2-41A3-ABC7-6341552DFA1BQ37397572-178BF418-2857-49CF-B255-9529529205EEQ37579925-BD86662D-1130-4849-86C2-A02C62D9E33AQ37658726-30C7DBA0-C9A5-40D6-A007-202C73510CA6Q37670073-99201612-E022-4F05-9395-FEA1F23FEC10Q37672187-21A75D20-476A-4ADD-A95F-CEAEBD04331BQ37778649-9E4C2424-C70A-460D-B2E9-3BFB08B3E5A3Q37888153-4232E316-96EB-49F5-B192-CBEDB22D195EQ38223284-838BF425-8FC6-492D-95C4-76D1F663B71EQ38403260-5AF07988-9C61-4A84-8490-2241BB5B5740Q38558926-7E0B6A3A-F513-406C-9BB4-1F3959A3A468Q38646953-F20C39F5-226C-4EBD-B478-34FE31438DE7Q38879877-9E522D69-FA4C-45F2-B92E-16C2110669D0Q39036058-545192F7-7F66-4448-BA38-2C19C604240FQ39151839-9156FBA5-DDBE-4731-883D-C554A7034032
P2860
Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Clinical aspects and molecular ...... roteins factor I and factor H.
@ast
Clinical aspects and molecular ...... roteins factor I and factor H.
@en
type
label
Clinical aspects and molecular ...... roteins factor I and factor H.
@ast
Clinical aspects and molecular ...... roteins factor I and factor H.
@en
prefLabel
Clinical aspects and molecular ...... roteins factor I and factor H.
@ast
Clinical aspects and molecular ...... roteins factor I and factor H.
@en
P2860
P1476
Clinical aspects and molecular ...... proteins factor I and factor H
@en
P2093
P2860
P304
P356
10.1111/J.1365-3083.2006.01729.X
P577
2006-03-01T00:00:00Z